Emergence of nalidixic acid resistance in Shigella sonnei isolated from patients having acute diarrheal disease: report from eastern province of Saudi Arabia.
During the 5 years of the study period (October 1999-October 2003), 110 strains of Shigella were isolated from fecal samples of patients having acute diarrheal diseases. Shigella sonnei phase 1 was the most prevalent (88/110, 80.0%) serotype. Resistance to nalidixic acid was not encountered from 1999-2002. Nalidixic acid resistance was observed in 6/13 (46.1%) of the S. sonnei phase 1 strains isolated from April-August 2003. Minimum inhibitory concentration to nalidixic acid among these strains was 48-96 microg/ml. All the six nalidixic acid resistant strains of S. sonnei phase 1 had reduced susceptibility (MIC 0.25 microg/ml) to ciprofloxacin.
Panhotra
Bodh Raj
BR
Division of Microbiology, Postgraduate Department of Medicine, King Fahad Hospital and Tertiary Care Center, Al-Hasa 31982, Saudi Arabia. drpanhotra2000@yahoo.co.in
Saxena
Anil Kumar
AK
Al-Mulhim
Khalifa
K
D000208:Acute Disease; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology; D015169:Colony Count, Microbial; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D004405:Dysentery, Bacillary / Q000188:drug therapy* / Q000382:microbiology; D005243:Feces / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D009268:Nalidixic Acid / Q000494:pharmacology*; D012529:Saudi Arabia; D012764:Shigella sonnei / Q000187:drug effects*
D000890:Anti-Infective Agents; D009268:Nalidixic Acid; D002939:Ciprofloxacin